ClinicalTrials.gg
CompletedNCT05535972Updated Dec 11, 2025Results posted

To Evaluate Real-World Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol (FF/UMEC/VI) in a Single Inhaler (Trelegy Ellipta) in Participants With Symptomatic COPD

A Phase 4 interventional study of FF/UMEC/VI in Pulmonary Disease, Chronic Obstructive, sponsored by GlaxoSmithKline. Completed at 1 site in China. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2025-12-11.

Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
463
Allocation
Not applicable
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies testing fluticasone furoate in Pulmonary Disease, Chronic Obstructive — 2 open to participants now, 2 under way, none of them phase 3. fluticasone furoate · Pulmonary Disease, Chronic Obstructive.

Enrollment
11th of 25
463 · median 229
Started
2022
the only one that year
Phase 4
13 of 25
2 open now
Registered
22nd of 25
by date
Lead sponsor
21 of 25
GlaxoSmithKline

Among the 25 studies testing fluticasone furoate in Pulmonary Disease, Chronic Obstructive, this one is the 11th largest by enrollment, is the only one that started in 2022, is one of 13 in phase 4, and was the 22nd registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

2 of the 25 studies testing fluticasone furoate in Pulmonary Disease, Chronic Obstructive are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About fluticasone furoate

fluticasone furoate: first FDA approval 2007 (FLONASE SENSIMIST ALLERGY RELIEF), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing fluticasone furoate in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the effectiveness of TRELEGY ELLIPTA on health status in participants with symptomatic COPD. The secondary objective is to evaluate the effectiveness of TRELEGY ELLIPTA on dyspnea and lung function in participants with symptomatic COPD. TRELEGY and ELLIPTA are trademarks of the GlaxoSmithKline group of companies.

03

Conditions studied

  • Pulmonary Disease, Chronic Obstructive

Keywords

  • TRELEGY ELLIPTA
  • Single Inhaler
  • Fluticasone Furoate
  • Umeclidinium Bromide
  • Vilanterol
  • FF/UMEC/VI
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be 40 years or above of age inclusive, at the time of signing the .
  • Participants with a documented physician diagnosis of .
  • CAT greater than or equal to (≥) 10.
  • Existing COPD Maintenance Treatment. Participants currently receiving one of the maintenance therapies given below who have been prescribed it continually for at least 12 weeks prior to screening (Visit 1): Inhaled / Long-Acting Beta-2-Agonists (ICS/LABA) (single or multiple inhalers); Long-Acting Muscarinic Antagonist (LAMA)/LABA (single or multiple inhalers); Free combination of inhaled corticosteroids (ICS), LAMA, LABA.
  • Current or former cigarette smokers with a history of cigarette smoking history ≥10 pack-years at screening.
  • Trelegy is prescribed under the discretion of clinical physicians with medical records providing documentation of a Trelegy prescription in daily practice.
  • Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.

Exclusion criteria

Exclusion Criteria:

  • Women who are pregnant or lactating or are planning on becoming pregnant during the study.
  • Prescribed with Trelegy within one year prior to screening (Visit 1).
  • Participants who, in the opinion of the treating investigator, are chronic users of oral for respiratory or other indications (if unsure discuss with the medical monitor prior to screening). Chronic use is defined as more than 14 days continuous use during the 12 weeks prior to Visit 1.
  • Participants with any life-threatening condition i.e. low probability, in the opinion of the investigator, of 3-month survival due to severity of or comorbid condition.
  • Participants with unstable COPD. Participants with resolution of an exacerbation less than 2 weeks prior to Visit 1. Participants may be rescreened 2 weeks after resolution of exacerbation (exacerbation is defined as: requiring treatment with antibiotics and/or systemic steroids or hospitalization; resolution is defined as: 2 weeks after all symptoms have resolved and any medicines to treat the exacerbation have finished).
  • Participants who need more than 3 liter per minute (L/min) supplemental oxygen at rest at screening.
  • Other diseases/abnormalities: Participants with historical or current evidence of uncontrolled or disease. Significant is defined as any disease that, in the opinion of the investigator, would put the safety of the participant at risk through participation, or which would affect the efficacy or safety analysis if the disease/condition exacerbated during the study.
  • Participant received any drug in other clinical trial within four weeks or 5 half-lives prior to this study whichever is longer.
  • Any conditions or illnesses listed in the section of in the Summary of Product Characteristics (SmPC) of Trelegy, i.e., to the active substances of TRELEGY ELLIPTA.
  • Participants with known COVID-19 positive contacts within the past 14 days.
  • Inability to read: In the opinion of the Investigator, any participant who is unable to read and/or would not be able to complete study related materials.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
463 participants (actual)

Study arms

  • Experimental
    Participants receiving TRELEGY ELLIPTA

    Participants will receive FF/UMEC/VI, inhalation powder, once daily, in a single device (TRELEGY ELLIPTA) for 12 weeks.

    Drug: FF/UMEC/VI

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in COPD Assessment Test (CAT) Score at Week 12

    The CAT is a validated 8-items questionnaire developed for use in routine clinical practice to measure the health status of participants with COPD. Participants rate their experience on a 6-point scale, ranging from 0 (no impairment) to 5 (maximum impairment), higher score indicates greater impairment. A total CAT score was calculated by summing the non-missing scores of the eight items with a scoring range of 0 (no disease impact) to 40 (maximum disease impact). Higher scores indicated greater disease impact. Baseline was defined as the latest pre-dose of Trelegy assessment with a non-missing value, including those from unscheduled visits. Change from Baseline (CFB) was calculated by subtracting Baseline value from the post-dose visit value.

    Time frame: Baseline (Day 1, pre-dose) and at Week 12

Secondary outcomes

  1. Change From Baseline in Modified Medical Research Council (mMRC) Grading System at Week 12 (Patient Version)

    mMRC(Patient Version\[Pt.V\]) was used to assess breathlessness state of participant before and after treatment. mMRC (Pt V) was completed by each participant firstly, without supervision.Participants were scored on a scale of 0 (no impact) to 4(worst possible impact) depending on their disability due to shortness of breath. Higher scores indicated greater disease impact;where 0=only get breathless with strenuous exercise;1=get short of breath when hurrying on the level/walking up a slight hill;2=walk slower than people of same age on the level because of breathlessness/have to stop for breath when walking at own pace on the level;3=stop for breath after walking about 100 yards/after a few minutes on the level;4=too breathless to leave house/breathless when dressing. Baseline=latest pre-dose of Trelegy assessment with a non-missing value, including those from unscheduled visits. Change from Baseline=post-dose visit value minus Baseline value.

    Time frame: Baseline (Day 1, pre-dose) and at Week 12

  2. Change From Baseline in Modified Medical Research Council (mMRC) Dyspnea Scale at Week 12 (Physician Version)

    mMRC(Physician Version\[PV\]) was used to assess breathlessness state of participant before and after treatment. Physicians completed mMRC(PV) through their observation. Participants were scored on a scale of 0 (no impact) to 4(worst possible impact) depending on their disability due to shortness of breath. Higher scores indicated greater disease impact; where 0=no breathlessness except on strenuous exercise; 1=shortness of breath when hurrying on the level ground or walking up a slight hill; 2=walks slower than people of same age on the level because of breathlessness or has to stop to catch breath when walking at their own pace on the level; 3=stops for breath after walking about 100 yards or after few minutes on level ground; 4=too breathless to leave house or breathless when dressing or undressing. Baseline=latest pre-dose of Trelegy assessment with a non-missing value, including those from unscheduled visits. Change from Baseline=post-dose visit value minus Baseline value.

    Time frame: Baseline (Day 1, pre-dose) and at Week 12

  3. Change From Baseline in Pre-dose Forced Expiratory Volume in 1 Second (FEV1) at Week 12

    FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. FEV1 was measured using spirometry. Baseline was defined as the latest pre-dose of Trelegy assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.

    Time frame: Baseline (Day 1, pre-dose) and at Week 12

  4. Percentage of Participants Having >=2 Unit Decrease in CAT Score From Baseline at Week 12

    The CAT is a validated 8-items questionnaire developed for use in routine clinical practice to measure the health status of participants with COPD. Participants rate their experience on a 6-point scale, ranging from 0 (no impairment) to 5 (maximum impairment), higher score indicates greater impairment. A total CAT score was calculated by summing the non-missing scores of the eight items with a scoring range of 0 (no disease impact) to 40 (maximum disease impact). Higher scores indicated greater disease impact. Baseline was defined as the latest pre-dose of Trelegy assessment with a non-missing value, including those from unscheduled visits. Percentage values are rounded-off. Percentage of participants having \>=2 unit decrease in CAT score from Baseline at week 12 has been presented.

    Time frame: Baseline (Day 1, pre-dose) and at Week 12

  5. Change From Baseline in COPD Assessment Test (CAT) Score at Week 4

    The CAT is a validated 8-items questionnaire developed for use in routine clinical practice to measure the health status of participants with COPD. Participants rate their experience on a 6-point scale, ranging from 0 (no impairment) to 5 (maximum impairment), higher score indicates greater impairment. A total CAT score was calculated by summing the non-missing scores of the eight items with a scoring range of 0 (no disease impact) to 40 (maximum disease impact). Higher scores indicated greater disease impact. Baseline was defined as the latest pre-dose of Trelegy assessment with a non-missing value, including those from unscheduled visits. Change from Baseline (CFB) was calculated by subtracting Baseline value from the post-dose visit value.

    Time frame: Baseline (Day 1, pre-dose) and at Week 4

  6. Number of Participants With Trelegy Related Non-serious Adverse Events (AEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention.

    Time frame: Up to 251 days

  7. Number of Participants With Trelegy Related Serious Adverse Events (SAEs)

    A SAE is defined as any serious adverse event that, at any dose; results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, a suspected transmission of any infectious agent via an authorized medicinal product or other situations as judged by physician.

    Time frame: Up to 251 days

  8. Number of Participants With Trelegy Related AEs Leading to the Discontinuation

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention.

    Time frame: Up to 251 days

07

Results

Posted Nov 4, 2024

Participant flow

Participant flow — Overall Study
MilestoneTrelegy (FF/UMEC/VI ELLIPTA)
Started463
Full analysis set460
Completed419
Not completed44
Withdrew: Withdrawal by subject31
Withdrew: Lost to follow-up5
Withdrew: Adverse event6
Withdrew: Protocol deviation2

Outcome measures

PrimaryChange From Baseline in COPD Assessment Test (CAT) Score at Week 12

The CAT is a validated 8-items questionnaire developed for use in routine clinical practice to measure the health status of participants with COPD. Participants rate their experience on a 6-point scale, ranging from 0 (no impairment) to 5 (maximum impairment), higher score indicates greater impairment. A total CAT score was calculated by summing the non-missing scores of the eight items with a scoring range of 0 (no disease impact) to 40 (maximum disease impact). Higher scores indicated greater disease impact. Baseline was defined as the latest pre-dose of Trelegy assessment with a non-missing value, including those from unscheduled visits. Change from Baseline (CFB) was calculated by subtracting Baseline value from the post-dose visit value.

Time frame:
Baseline (Day 1, pre-dose) and at Week 12
Reported as:
Mean · Scores on a scale
Change From Baseline in COPD Assessment Test (CAT) Score at Week 12
Scores on a scaleTrelegy (FF/UMEC/VI ELLIPTA)
Change From Baseline in COPD Assessment Test (CAT) Score at Week 12-6.8 ± 5.49
Statistical analysis
  • Trelegy (FF/UMEC/VI ELLIPTA) · Least square mean: -6.81 · 95% CI -7.28 to -6.33CFB in CAT score was analyzed using Mixed Model Repeated Measures(MMRM) model with covariates of smoking status, CAT score at Baseline, visit, interaction of CAT score at Baseline\*visit. Estimates derived from inverse probability weighted MMRM model.
SecondaryChange From Baseline in Modified Medical Research Council (mMRC) Grading System at Week 12 (Patient Version)

mMRC(Patient Version\[Pt.V\]) was used to assess breathlessness state of participant before and after treatment. mMRC (Pt V) was completed by each participant firstly, without supervision.Participants were scored on a scale of 0 (no impact) to 4(worst possible impact) depending on their disability due to shortness of breath. Higher scores indicated greater disease impact;where 0=only get breathless with strenuous exercise;1=get short of breath when hurrying on the level/walking up a slight hill;2=walk slower than people of same age on the level because of breathlessness/have to stop for breath when walking at own pace on the level;3=stop for breath after walking about 100 yards/after a few minutes on the level;4=too breathless to leave house/breathless when dressing. Baseline=latest pre-dose of Trelegy assessment with a non-missing value, including those from unscheduled visits. Change from Baseline=post-dose visit value minus Baseline value.

Time frame:
Baseline (Day 1, pre-dose) and at Week 12
Reported as:
Mean · Scores on a scale
Change From Baseline in Modified Medical Research Council (mMRC) Grading System at Week 12 (Patient Version)
Scores on a scaleTrelegy (FF/UMEC/VI ELLIPTA)
Change From Baseline in Modified Medical Research Council (mMRC) Grading System at Week 12 (Patient Version)-0.5 ± 0.91
SecondaryChange From Baseline in Modified Medical Research Council (mMRC) Dyspnea Scale at Week 12 (Physician Version)

mMRC(Physician Version\[PV\]) was used to assess breathlessness state of participant before and after treatment. Physicians completed mMRC(PV) through their observation. Participants were scored on a scale of 0 (no impact) to 4(worst possible impact) depending on their disability due to shortness of breath. Higher scores indicated greater disease impact; where 0=no breathlessness except on strenuous exercise; 1=shortness of breath when hurrying on the level ground or walking up a slight hill; 2=walks slower than people of same age on the level because of breathlessness or has to stop to catch breath when walking at their own pace on the level; 3=stops for breath after walking about 100 yards or after few minutes on level ground; 4=too breathless to leave house or breathless when dressing or undressing. Baseline=latest pre-dose of Trelegy assessment with a non-missing value, including those from unscheduled visits. Change from Baseline=post-dose visit value minus Baseline value.

Time frame:
Baseline (Day 1, pre-dose) and at Week 12
Reported as:
Mean · Scores on a scale
Change From Baseline in Modified Medical Research Council (mMRC) Dyspnea Scale at Week 12 (Physician Version)
Scores on a scaleTrelegy (FF/UMEC/VI ELLIPTA)
Change From Baseline in Modified Medical Research Council (mMRC) Dyspnea Scale at Week 12 (Physician Version)-0.5 ± 0.89
SecondaryChange From Baseline in Pre-dose Forced Expiratory Volume in 1 Second (FEV1) at Week 12

FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. FEV1 was measured using spirometry. Baseline was defined as the latest pre-dose of Trelegy assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.

Time frame:
Baseline (Day 1, pre-dose) and at Week 12
Reported as:
Mean · Liters
Change From Baseline in Pre-dose Forced Expiratory Volume in 1 Second (FEV1) at Week 12
LitersTrelegy (FF/UMEC/VI ELLIPTA)
Change From Baseline in Pre-dose Forced Expiratory Volume in 1 Second (FEV1) at Week 120.132 ± 0.2897
SecondaryPercentage of Participants Having >=2 Unit Decrease in CAT Score From Baseline at Week 12

The CAT is a validated 8-items questionnaire developed for use in routine clinical practice to measure the health status of participants with COPD. Participants rate their experience on a 6-point scale, ranging from 0 (no impairment) to 5 (maximum impairment), higher score indicates greater impairment. A total CAT score was calculated by summing the non-missing scores of the eight items with a scoring range of 0 (no disease impact) to 40 (maximum disease impact). Higher scores indicated greater disease impact. Baseline was defined as the latest pre-dose of Trelegy assessment with a non-missing value, including those from unscheduled visits. Percentage values are rounded-off. Percentage of participants having \>=2 unit decrease in CAT score from Baseline at week 12 has been presented.

Time frame:
Baseline (Day 1, pre-dose) and at Week 12
Reported as:
Number · Percentage of Participants
Percentage of Participants Having >=2 Unit Decrease in CAT Score From Baseline at Week 12
Percentage of ParticipantsTrelegy (FF/UMEC/VI ELLIPTA)
Percentage of Participants Having >=2 Unit Decrease in CAT Score From Baseline at Week 1286.0 (82.7 to 89.3)
SecondaryChange From Baseline in COPD Assessment Test (CAT) Score at Week 4

The CAT is a validated 8-items questionnaire developed for use in routine clinical practice to measure the health status of participants with COPD. Participants rate their experience on a 6-point scale, ranging from 0 (no impairment) to 5 (maximum impairment), higher score indicates greater impairment. A total CAT score was calculated by summing the non-missing scores of the eight items with a scoring range of 0 (no disease impact) to 40 (maximum disease impact). Higher scores indicated greater disease impact. Baseline was defined as the latest pre-dose of Trelegy assessment with a non-missing value, including those from unscheduled visits. Change from Baseline (CFB) was calculated by subtracting Baseline value from the post-dose visit value.

Time frame:
Baseline (Day 1, pre-dose) and at Week 4
Reported as:
Mean · Scores on a scale
Change From Baseline in COPD Assessment Test (CAT) Score at Week 4
Scores on a scaleTrelegy (FF/UMEC/VI ELLIPTA)
Change From Baseline in COPD Assessment Test (CAT) Score at Week 4-4.4 ± 5.29
SecondaryNumber of Participants With Trelegy Related Non-serious Adverse Events (AEs)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention.

Time frame:
Up to 251 days
Reported as:
Count of participants · Participants
Number of Participants With Trelegy Related Non-serious Adverse Events (AEs)
ParticipantsTrelegy (FF/UMEC/VI ELLIPTA)
Number of Participants With Trelegy Related Non-serious Adverse Events (AEs)9
SecondaryNumber of Participants With Trelegy Related Serious Adverse Events (SAEs)

A SAE is defined as any serious adverse event that, at any dose; results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, a suspected transmission of any infectious agent via an authorized medicinal product or other situations as judged by physician.

Time frame:
Up to 251 days
Reported as:
Count of participants · Participants
Number of Participants With Trelegy Related Serious Adverse Events (SAEs)
ParticipantsTrelegy (FF/UMEC/VI ELLIPTA)
Number of Participants With Trelegy Related Serious Adverse Events (SAEs)1
SecondaryNumber of Participants With Trelegy Related AEs Leading to the Discontinuation

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention.

Time frame:
Up to 251 days
Reported as:
Count of participants · Participants
Number of Participants With Trelegy Related AEs Leading to the Discontinuation
ParticipantsTrelegy (FF/UMEC/VI ELLIPTA)
Number of Participants With Trelegy Related AEs Leading to the Discontinuation5

Adverse events

Collected over All-cause mortality, non-serious adverse events (non-SAEs) and serious adverse events (SAEs) were collected up to 251 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Trelegy (FF/UMEC/VI ELLIPTA)2/460 (0.4%)19/460 (4.1%)10/460 (2.2%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventTrelegy (FF/UMEC/VI ELLIPTA)
COVID-19Infections and infestations3/460
Pneumothorax spontaneousRespiratory, thoracic and mediastinal disorders2/460
Lower respiratory tract infectionInfections and infestations1/460
Pneumonia pseudomonalInfections and infestations1/460
Viral infectionInfections and infestations1/460
Chronic respiratory failureRespiratory, thoracic and mediastinal disorders1/460
DyspnoeaRespiratory, thoracic and mediastinal disorders1/460
ArrhythmiaCardiac disorders1/460
Coronary artery diseaseCardiac disorders1/460
Ventricular extrasystolesCardiac disorders1/460
Most frequent other events
Showing 10 of 11
Most frequent other events
EventTrelegy (FF/UMEC/VI ELLIPTA)
DysphoniaRespiratory, thoracic and mediastinal disorders2/460
Respiratory tract irritationRespiratory, thoracic and mediastinal disorders1/460
Throat irritationRespiratory, thoracic and mediastinal disorders1/460
Abdominal discomfortGastrointestinal disorders1/460
Abdominal pain upperGastrointestinal disorders1/460
RashSkin and subcutaneous tissue disorders1/460
UrticariaSkin and subcutaneous tissue disorders1/460
DizzinessNervous system disorders1/460
HeadacheNervous system disorders1/460
Chest discomfortGeneral disorders1/460

Baseline characteristics

Baseline Characteristic data are reported for the Full Analysis Set (FAS) which included all participants who were enrolled into the study and took at least one dose of Trelegy.

Age, Continuous
Age, Continuous(Years)Trelegy (FF/UMEC/VI ELLIPTA)
Mean68.74 ± 8.118
Sex: Female, Male
Sex: Female, Male(Participants)Trelegy (FF/UMEC/VI ELLIPTA)
Female26
Male434
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Trelegy (FF/UMEC/VI ELLIPTA)
American Indian or Alaska Native0
Asian460
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
08

Study locations

1 site
  • GSK Investigational Site
    Dongguan, 523326, China
09

References and documents

Publications

  • Ma J, Dou F, Zhou W, Li L, Zhu J, Zhang Y, Zhou L, Su L, Dong L, He Y, Ye A, Slade D, Zheng J. Real-world effectiveness of single-inhaler fluticasone furoate/umeclidinium bromide/vilanterol in Chinese patients with symptomatic chronic obstructive pulmonary disease (COPD): a post-marketing, prospective, multicenter, observational study. Curr Med Res Opin. 2025 Jul;41(7):1363-1372. doi: 10.1080/03007995.2025.2536600. Epub 2025 Jul 29. PubMed 40704458 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk-studyregister.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2022 to primary completion in Sep 2023, 11 months.

Results were first posted in Nov 2024, 1 year 1 month after primary completion.

Of 71 industry-sponsored phase 4 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 22. This study's 11 months is below that.

Counting every sponsor, half of 157 studies reached it within 19 months; a quarter within 12 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 7, 2022
First posted
Sep 10, 2022
StartActual
Oct 14, 2022
Primary completionActual
Sep 25, 2023
CompletionActual
Sep 25, 2023
Results first posted
Nov 4, 2024
Last update
Dec 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05535972
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Sep 10, 2022
Start date
Oct 14, 2022
Primary completion
Sep 25, 2023
Completion
Sep 25, 2023
Results posted
Nov 4, 2024
Last update
Dec 11, 2025

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fluticasone furoate · GSK573719 · Vilanterol

Start the discussion